Zymeworks Inc. (ZYME)

Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER...

Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3 ...

After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have h...

Despite (or perhaps because of) the volatility in the stock market and uncertainty about the economy, insiders are still scooping up shares of certain stocks.

On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.

Zymeworks Inc. (NASDAQ:ZYME ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, ...

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.20 per share a year ago.